medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2006; 5 (4)


Interferon alfa-2b triggers transforming growth factor-β1-induced apoptosis on preneoplastic liver

Cristina CM, Luján ÁM, Darío QA

Idioma: Ingles.
Referencias bibliográficas: 65
Paginas: 244-250
Archivo PDF: 136.99 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Isaacs A, Lindenman J. Virus interference I. The interferon. Proc R Soc 1957; 147: 258-267.

  2. Tyrell DAJ. Research on Interferon: a review. J Roy Soc Med 1981;74: 145-146.

  3. Interferon nomenclature. Nature 1980; 286: 110.

  4. Haque SJ, Williams BR. Signal transduction in the interferon system. Semin Oncol 1998; 25(Suppl. 1): 14-22.

  5. Merlin G, Falcoff E, Aguet M. 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data. J Gen Virol 1985; 66: 1149-1152.

  6. Stark GR, Kerr IM, Williams BRG, Silverman RH, Schreiber RD. How cells respond to Interferon. Annu Rev Biochem 1998; 67: 227-264.

  7. Jonash E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 2001; 6: 34-55.

  8. Svreevalsan T. Biological Therapy with interferon alfa and beta: preclinical studies. In: De Vita VTJ, Hellman SMD, Rosenberg SA, eds. Biology Therapy of Cancer. Second Ed. Philadelphia: J.B.Lippincot Company, 1995: 347-364.

  9. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, Cella M, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmocytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805.

  10. Coccia EM, Uzé G, Pellegrini S. Negative regulation of type I interferon signaling: facts and mechanisms. Cell Mol Biol 2006; 52: 77-87.

  11. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lynphoblastoid interferon: in vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986; 2: 419-429.

  12. Wong S, Gauthier T, Kalta K, Minuk G. The differential effects of three forms of interferon alfa on hepatic regeneration after parcial hepatectomy in the rat. Hepatology 1995; 22: 883-886.

  13. Favre C, Carnovale C, Monti J, Carrillo MC. Inhibition by interferon alpha-2b of rat liver regeneration: effect on ornithine decarboxylase and total protein synthesis. Biochem Pharmacol 2001; 61: 1587-1593.

  14. Rosemberg SA. Principles of cancer management: biologic therapy. In: De Vita V, Hellman S, Rosemberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1997: 349-373.

  15. Zurita M, Cabrera MM, Morales C, Oya S, Vaquero J. Influence of the postnatal administration of tumor necrosis factor plus interferon að-2b on the development of ethyl-nitrosourea-induced brain tumors in rats. Neuroscience Letters 1994; 174: 213-216.

  16. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus. Cancer 1998; 82: 827-835.

  17. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National Surveillance Program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-181.

  18. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M, Bourliere M, et al. Treatment of hepatitis C virus-related cirrhosis. A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999; 29: 1870-1875.

  19. Llovet J, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, Ayuso C, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000; 31: 54-58.

  20. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-1205.

  21. Motola-Kuba D, Zamora-Valdés D, Uribe M, Méndez-Sánchez N. Hepatocellular carcinoma. An overview. Ann Hepatol 2006; 5: 16-24.

  22. Stewart HL. Comparative aspects of certain cancers. In: Becker, FF, ed. Cancer. A Comprehensive Treatise. New York: Plenum Press, 1975: 303-374.

  23. Williams GM. The significance of chemically induced hepatocellular altered foci in rat liver and application to carcinogen detection. Toxicol Pathol 1989; 17: 663-672.

  24. Pitot HC, Campbell HA, Maronpot R, Bawa N, Rizvi TA, Xu YH, Sargent L, et al. Critical parameters in the quantitation of the stages of initiation, promotion and progression in one model of hepatocarcinogenesis in the rat. Toxicol Pathol 1989; 17: 594-612.

  25. Altmann HW. Hepatic neoformations. Pathol Res Pract 1994; 190: 513-577.

  26. Farber E, Sarma D. Chemical carcinogenesis: the liver as a model. Pathol Imnunophatol Res 1986; 5: 1-28.

  27. Goldsworthy T, Hanigan M, Pitot H. Models of hepatocarcinogenesis in the rat: contrasts and comparisons. Crit Rev Toxicol 1986; 17: 61-89.

  28. Solt D, Farber E. New principle for analysis of chemical carcinogenesis. Nature 1976; 263: 701-703.

  29. Ito N, Tsuda H, Tatematsu M, Inove T, Tagawa Y, Aoki T, Umegawa S, et al. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats: an approach for a new medium term bioassay system. Carcinogenesis 1988; 9: 387-394.

  30. Rao P, Nagamine Y, Roomi M, Rajalaskshmi S, Sarma D. Orotic acid, a new promoter for experimental liver carcinogenesis. Toxicol Pathol 1984; 12: 173-178.

  31. Peraino C, Staffeldt EF, Carnes BA, Ludemar VA, Blomquist JA, Vesselinovitch SD. Characterization of histochemically detectable altered hepatocyte foci and their relationship to hepatic tumorigenesis in rats treated once with diethylnitrosamine or benzo[a]pyrene within one day of birth. Cancer Res 1984; 44: 3340-3347.

  32. Pitot H, Barsness L, Goldsworthy T, Kitagawa T. Biochemical characterization of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature 1978; 271: 456-458.

  33. Becker RA, Shank RC. Kinetics of formation and persistence of ethylguanines in DNA in rats and hamsters treated with diethylnitrosamine. Cancer Res 1985; 45: 2076-2084.

  34. Alvarez ML, Cerliani JP, Monti J, Carnovale C, Ronco MT, Pisan G, Lugano MC, Carrillo MC. The in vivo apoptotic effect of Interferon α-2b on rat preneoplastic liver involves Bax protein. Hepatology 2002; 35(4): 824-833.

  35. Zörnig M, Hueber A-O, Baum W, Evan G. Apoptosis regulators and their role in tumorigenesis. Biochimica et Biophysica Acta 2001; 1151: F1-F37.

  36. Zimmermann KC, Green DR. How cells die: apoptosis pathways. J Allergy Clin Immunol 2001; 108: S99-103.

  37. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4: 592-603.

  38. Krammer PH. CD95’s deadly mission in the immune system. Nature 2000; 407: 789-795.

  39. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.

  40. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132.

  41. Goldstein JC, Waterhouse NJ, Juin P, Evan GI, Green DR. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biol 2000; 2: 156-162.

  42. Creasey AA, Bartholome JC, Merigan TC. Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 1980; 77: 1471-1475.

  43. Ross G, Leanderson T, Lundgren T. Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemic cells.Cancer Res 1984; 44: 2358-2362.

  44. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of p53-dependent negative response element in the Bcl-2 gene. Cancer Res 1994; 54: 3131-3135.

  45. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.

  46. Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ 1997; 8: 343-352.

  47. Rodríguez-Villanueva J, Mc Donnell TJ. Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int J Cancer 1995; 61: 110-114.

  48. Nechushstan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999; 18: 2330-2341.

  49. Massague J, Blain SW, Lo RS TGF-β signaling in growth control, cancer, and heritable disorders. Cell 2000; 103: 295-309.

  50. Fynan TM, Reiss M. Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Oncog 1993; 5: 493-540.

  51. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998; 67: 753-91.

  52. Herrera B, Fernández M, Álvarez AM, Roncero C, Benito M, Gil J, Fabregat I. Activation of caspases occurs downstream from radical oxygen species production, Bcl-xL down-regulation, and early cytochrome c release in apoptosis induced by transforming growth factor β in rat fetal hepatocytes. Hepatology 2001; 34: 548-556.

  53. Chen J, Gokhale M, Schofield B, Odwin S, Yager JD. Inhibition of TGF-β-induced apoptosis by ethinyl estradiol in cultured precision cut rat liver slices and hepatocytes. Carcinogenesis 2000; 21: 1205-1211.

  54. Yamamoto M, Fukuda K, Miura N, Suzuki R, Kido T, Komatsu Y. Inhibition by dexamethasone of transforming growth factor β1-induced apoptosis in rat hepatoma cells: A possible association with Bcl-xL induction. Hepatology 1998; 27: 959-966.

  55. Teramoto T, Kiss A, Thorgeirsson SS. Induction of p53 and Bax during TGF-β1 initiated apoptosis in rat epithelial cells. Biochem Biophys Res Commun 1998; 251: 56-60.

  56. Christensen JG, Goldsworthy TL, Cattley RC. Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and non-genotoxic carcinogens. Mol Carcinog 1999; 5: 185-191.

  57. Shima Y, Nakao K, Nakashima T, Kawakami A, Nakata K, Hamasaki K, Kato Y, et al. Activation of caspase-8 in transforming growth factor-β-induced apoptosis of human hepatoma cells. Hepatology 1999; 30: 1215-1222.

  58. Huang YL, Chou CK. Bcl-2 blocks apoptotic signal of transforming growth factor-beta in human hepatoma cells. J Biomed Sci 1998; 5: 185-191.

  59. Hori Y, Takeyama Y, Ueda T, Shinkai M, Takase K, Kuroda Y. Macrophage-derived transforming growth factor-β1 induces hepatocellular injury via apoptosis in severe acute pancreatitis. Surgery 2000, 127:641-649.

  60. Wickenhauser C, Schmitz B, Selbach B, Brockbals C, Manske O, Thiele J. Interferon α2b directly induces fibroblast proliferation and transforming growth factor β secretion on macrophages. Br J Haematol 2000, 109:296-304.

  61. Alvarez ML, Ronco MT, Monti JA, Carnovale C, Ochoa E, Pisani G, Lugano MC, Carrillo MC. Hepatocytic Transforming Growth Factor β 1 is involved in interferon alfa-2b-induced apoptosis on rat preneoplastic liver. Hepatology 2004; 40(2): 394-402.

  62. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, Takaishi K, Kiso S, et al. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma. Cancer 1994; 73: 2275-2279.

  63. Bissell DM, Wang S-S, Jarnagin WR, Roll FJ. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995; 96: 447-55.

  64. Chade AR, Bentley MD, Zhu X, Rodriguez-Porcel M, Niemeyer S, Amores-Arriaga B, Napoli C, Ritman EL, Lerman A, Lerman LO. Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. J Am Soc Nephrol 2004; 15: 1816-1825.

  65. Zhan CD, Sindhu RK, Vaziri ND. Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: reversal by lifelong antioxidant supplementation. Kidney Int 2004; 65: 219-27.




2020     |     www.medigraphic.com